image credit- shutterstock
South Korea-based Mezzion Pharma Co., a leader in rare disease therapeutics, has announced the expansion of its udenafil pipeline with the initiation of a pre-clinical study for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
This initiative builds on Mezzion's rare disease expertise in cardiovascular and hepatic conditions and marks a strategic expansion into the high-need area of renal disorders. The study is being conducted in collaboration with Mayo Clinic expert Dr Fouad Chebib.
ADPKD, a prevalent genetic disorder characterized by the growth of numerous kidney cysts, affects about 1 in 400 to 1,000 people worldwide. The disease progressively impairs kidney function, often leading to kidney failure. Current treatment options are limited and often associated with severe side effects, highlighting a significant unmet need for safer, more effective treatments.
The ADPKD treatment market is poised for significant growth, with projections estimating it could approach $3 billion by the early 2030s. Udenafil's potential to address this unmet need with a differentiated safety and efficacy profile positions Mezzion for long-term value creation.
